SNC102 / Shanghai Simnova Bio - LARVOL DELTA

Phase I Clinical Study of Humanized BCMA-Single-Domain Antibodies-Targeting CAR T (BCMA-CART) in Patients with Relapsed/Refractory Multiple Myeloma (ASH 2023) - P1 | "After lymphatic preconditioning chemotherapy (program: fludarabine 30mg/m2/d and cyclophosphamide 300mg/m2/d, -5, -4, -3, for 3 consecutive days), all patients received a single dose of CART-BCMA at 2.5×106, 5×106 and 7.5×106 CAR-positive T cells/kg (subject body weight), according to the dose level in which they were enrolled...After the occurrence of CRS, all patients recovered without sequelae after supportive treatment, and 6 patients (40%) received tocilizumab (3 subjects received 2 doses, 3 subjects received 1 dose), 4 patients (26.7%) used glucocorticoids...Data from this phase 1 clinical study showed that CART-BCMA is well tolerated and highly efficacious in patients with RRMM. Patients with extramedullary plasmacytoma had the comparable response to those without extramedullary diseases. Notably, 12 patients (80%) patients elicted deeper response after 3 months of CART-BCMA infusion"

Clinical • P1 data • Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology • Plasmacytoma • Transplantation • CD8

Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: Shanghai Simnova Biotechnology Co.,Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: May 2023 ➔ Dec 2024

Enrollment closed • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Shanghai Simnova Biotechnology Co.,Ltd.

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology